Q2 2026 saw record ARCALYST revenue, up 55% year-over-year, and raised full-year guidance to $980–995 million. KPL-387 advanced to phase III with strong phase II data, and cash reserves grew to $525.9 million. Market penetration and prescriber base both expanded.Based on Kiniksa Pharmaceuticals Int…
Q2 2026 saw record ARCALYST revenue, up 55% year-over-year, and raised full-year guidance to $980–995 million. KPL-387 advanced to phase III with strong phase II data, and cash reserves grew to $525.9 million. Market penetration and prescriber base both expanded.
Based on
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
